Provectus Biopharmaceuticals, Inc.

Warrants SEC Reporting - Current
Verified Company Profile 10/04/2017
Contact Info
  • 10025 Investment Drive
  • Suite 250
  • Knoxville, TN 37932

Business Description

Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Audited
Latest Report Jun 30, 2017 10-Q
CIK 0000315545
Fiscal Year End 12/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2002
Employees 2 a/o Apr 28, 2017
Company Officers/Contacts
Timothy C. Scott, Ph.D. President, Principal Executive Officer
Eric Wachter, Ph.D. CTO
Company Directors
Dominic Rodrigues Chairman, Independent Director
Bruce Horowitz Independent Director
Jan E. Koe
Eric Wachter, Ph.D.
Service Providers
Accounting/Auditing Firm
Marcum LLP
750 Third Ave
11th Floor
New York, NY, 10017
United States
Securities Counsel
Baker Donelson Bearman Caldwell & Berkowitz
211 Commerce Street
Suite 800
Nashville, TN, 37201
United States
Investor Relations Firm

Not Available
Company History
  • Formerly=Provectus Pharmaceutical, Inc. until 1-2014
  • Formerly=Zamage Digital Imaging, Inc. until 4-02
  • Note=4-1-02 State of Incorporation Colorado changed to Nevada
  • Note=12-31-04 company is in the development stage
  • Formerly=SPM Group, Inc. until 11-01
PVCTW Security Details Other Company Securities
Share Structure
Market Value1 $227,859 a/o Oct 20, 2017
Authorized Shares 28,482,344 a/o Jun 30, 2016
Outstanding Shares 28,482,344 a/o Jun 30, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Transfer Agent(s)
Shareholders of Record Not Available
Short Selling Data
Short Interest 2,780 (0%)
Sep 29, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security